Therapeutic Potential and Mechanisms of Mesenchymal Stem Cell and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Atopic Dermatitis
Kang He,Jie Zang,Tingting Ren,Shaojie Feng,Mohan Liu,Xude Zhang,Wenchang Sun,Jinjin Chu,Donghua Xu,Fengxia Liu
DOI: https://doi.org/10.2147/jir.s479444
IF: 4.5
2024-09-01
Journal of Inflammation Research
Abstract:Kang He, 1, &ast Jie Zang, 2, &ast Tingting Ren, 1, &ast Shaojie Feng, 3 Mohan Liu, 1 Xude Zhang, 3 Wenchang Sun, 2 Jinjin Chu, 2 Donghua Xu, 2 Fengxia Liu 3 1 Department of Clinical Medicine of Shandong Second Medical University, Weifang, People's Republic of China; 2 Central Laboratory, Weifang People's Hospital, Shandong Second Medical University/Weifang People's Hospital, Weifang, People's Republic of China; 3 Department of Allergy, Weifang People's Hospital, Shandong Second Medical University, Weifang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Donghua Xu; Fengxia Liu, Email ; Atopic dermatitis (AD) is a chronic and inflammatory skin disease with intense itchiness that is highly prevalent worldwide.The pathogenesis of AD is complex and closely related to genetic factors, immunopathogenic factors, environmental factors, and skin infections. Mesenchymal stem cells (MSCs) are non-hematopoietic progenitor cells derived from the mesenchymal stroma. They have anti-inflammatory, anti-apoptotic, and regenerative properties. Numerous studies demonstrate that MSCs can play a therapeutic role in AD by regulating various immune cells, maintaining immune homeostasis, and promoting the repair of damaged tissues. The key mediators for their biological functions are extracellular vesicles (MSC-Evs) and soluble cytokines derived from MSCs. The safety and efficacy of MSCs have been demonstrated in clinical Phase I / IIa trials for AD. This paper provides a comprehensive review of the pathogenesis of AD and the currently published studies on the function of MSCs and MSC-Evs in AD, primarily including the pathogenesis and the immunomodulatory impacts of MSCs and MSC-Evs, along with advancements in clinical studies. It provides insights for comprehending AD pathogenesis and investigating treatments based on MSCs. Keywords: atopic dermatitis, mesenchymal stem cells, Th2-associated immunity, extracellular vesicle Atopic dermatitis (AD) is a skin disease that is chronic and inflammatory. It causes intense itching, redness, and flaking of the skin, and tends to relapse over time. The disease is highly prevalent globally, especially in affluent nations, with 20% of children and 10% of adults afflicted by it. This places a considerable burden on human health and social healthcare. 1,2 AD's intricate pathogenesis primarily involves genetic elements, epidermal barrier defects, immunopathogenic aspects, and environmental factors. 3 Dysregulated T and B cells and the induced Th2-associated immunity play crucial roles in AD. Although more therapeutic agents are now available on the market, traditional therapies such as oral antihistamines, topical cortisol, and calcium-modulated phosphatase inhibitors are only effective in patients with mild to moderate AD. For patients with severe AD, Janus kinase inhibitors and IL-4R alpha receptor blockers are effective in improving dermatitis and itching, but they also carry the risk of serious adverse effects, such as immunosuppression and infections. Moreover, they are expensive and prone to relapse after discontinuation. 4,5 Therefore, exploring effective therapeutic strategies for AD is of great importance. Mesenchymal stem cells (MSCs) are a group of pluripotent progenitor cells that can be found in most tissues. They have the ability to self-renew and diversify, and they also possess low immunogenicity and high immunomodulatory properties. MSCs commonly express membrane molecules, such as CD73 and CD90, while not expressing CD14, CD34, CD45, and HLA-DR. The lack of expression of immunostimulatory molecules makes MSCs immunocompatible. 6 MSCs can be derived from various tissues like bone marrow, adipose tissue, umbilical cord, periodontal tissue, umbilical cord blood, and placenta. 7 However, different tissue-derived MSCs vary in their differentiation ability and immunomodulatory capacity. Among them, adipose tissue-derived MSCs (Ad-MSCs), bone marrow-derived MSCs (BM-MSCs), and umbilical cord-derived MSCs (UC-MSCs) are commonly used in stem cell therapy research due to their high proliferation rate and immunosuppressive ability, 8–10 MSCs can modulate the innate and adaptive immune systems by altering macrophage immune phenotype, promoting anti-inflammatory cytokine production, inhibiting natural killer (NK) cell growth and cytokine release, and suppressing the growth and differentiation of T and B cells. 11 Increasing evidence suggests that MSCs are critical in regulating inflammation and autoimmunity in AD. MSC exerts its therapeutic effects on AD through cellular interactions an -Abstract Truncated-
immunology